Experience with urine drug testing by the Correctional Service of Canada

The Correctional Service of Canada implemented a urine drug-screening program over 10 years ago. The objective of this report is to describe the program and drug test results in this program for 1999. Offenders in Canadian federal correctional institutions and those living in the community on conditional release were subject to urine drug testing. Urine specimens were collected at correctional facilities and shipped by courier to MAXXAM Analytics Inc. laboratory. All urine specimens were analyzed for amphetamines, cannabinoids, cocaine metabolite (benzoylecgonine), opiates, phencyclidine, benzodiazepines, methyl phenidate, meperidine, pentazocine and fluoxetine by immunoassay screening (homogeneous EIA and ELISA assays) followed by GC-MS confirmation. Ethyl alcohol was analyzed when specifically requested. Alternative screening and confirmation methods with lower cut-off values were used, whenever urine specimens were dilute (creatinine <20mg/dl and specific gravity 相似文献   

Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market

1-Aryl-piperazine compounds are, depending on their substituents, selective for certain serotonin receptors and together with their easy availability and their so-called legal status, this group of psychoactive compounds are potential designer drugs-of-abuse. Internet in that respect is an important source of information and distribution facilities. Because this development may have consequences for the interpretation of future clinical and forensic toxicological case studies, some analytical aspects of 1-benzyl-piperazine (BZP), 1-[4-methoxyphenyl]-piperazine (pMeOPP) and 1-[3-trifluoromethylphenyl]-piperazine (TFMPP) were studied. BZP was not detected by the AxSYM FPIA technology designed to determine amphetamine-like compounds, but had showed some cross reactivity with EMIT d.a.u.. The cross reactivities at 300 and 12,000ng/ml (RS)-amphetamine equivalents were 0.4 and 1.3%, respectively. Although BZP was not identified directly by the REMEDi HS Drug Profiling System, it can be detected by this HPLC/UV scanning system. Using GC/NPD without derivatisation, BZP, pMeOPP and TFMPP can be analysed for and applying GC/MS without or with acetylation or trifluoroacetylation, these compounds can be identified unambiguously. The usefulness of GC/NPD and GC/MS in this respect was demonstrated by the quantitative and qualitative analysis of the content of a capsule with the synthetic stimulant A2, which proved to contain 86.4mg of BZP.     

Spectra interference between diquat and paraquat by second derivative spectrophotometry

A rapid and accurate method, combining solid-phase extraction and second-order derivative spectrophotomety approaches, is developed for the simultaneous determination of diquat (DQ) and paraquat (PQ) in blood, tissue and urine samples. Supernatant resulting from the precipitation of protein (with trichloroacetic acid) in plasma and tissue or Amberlite IRA-401 resin treated urine are passed through a mini-column packed with Wakogel gel (Silica gel). Analytes are then eluted with a non-organic solvent, 0.2mol/l HCl solution containing 2mol/l NH(4)Cl. UV spectrum of the eluent in 220-350nm range provides effective screen to detect the presence of DQ and/or PQ. In the presence of DQ or PQ alone, the analyte present is quantitated by conventional zero- or second-order derivative spectrophotometry. The calibration curve in the 0.1-5.0mg/l range for either analyte obeys Beer's law. When both DQ and PQ are present, their concentrations are determined by the peak amplitudes of their respective second-derivative spectra after the addition of alkaline dithionite reagent. Interference is negligible when the DQ/PQ concentration ratio is within the 5.0-0.2 range.Using a 2-ml of sample size, the detection limits for DQ and PQ in plasma are 0.02 and 0.005mg/l. The corresponding detection limits for urine samples (10ml sample size) are 0.004 and 0.001mg/l. Recoveries of DQ and PQ in triplicate plasma and urine samples spiked with 0.5mg/l of analytes are 93 and 85%. The precision of the proposed method resulting from triplicate study of spiked urine samples varies from 3.2 to 4.6% at 0.5mg/l of DQ and PQ, respectively.     

大鼠脑挫伤后FN表达与损伤时程关系的研究

为寻找推断脑损伤经历时间的可靠指标,采用自制自由落体撞击法致大鼠右顶叶局灶性脑挫伤模型,于不同时间段处死大鼠后,进行纤维连接蛋白的免疫组织化学及原位杂交法研究,结果发现纤维连接蛋白及其 mRNA表达水平与伤后经历时间有一定相关性,并能较好地鉴别死前脑挫伤和死后脑挫伤,可作为推断脑挫伤经历时间的参考指标之一。     

低氧和氧化应激中 NO介导培养神经元损伤机理的实验研究

目的探讨低氧、氧化应激中一氧化氮（NO）和氧自由基之间关系及其对培养神经元的损伤机理。方法对培养的新生大鼠神经细胞分别进行低氧、H2O2氧化应激处理和超氧化物歧化酶（SOD）抗氧化应激处理,用比色法等检测培养上清液中NO、丙二醛（MDA）、乳酸脱氢酶（LDH）和SOD含量变化指标。结果与对照组比较,低氧组和H2O2组的NO、LDH、MDA含量均显著增高,SOD含量显著降低,NO与SOD含量变化呈负相关关系。预先给予终浓度为200U/ml的SOD处理,可使神经细胞的NO、LDH和MDA释放量明显减少。各组间NO含量与LDH、MDA含量呈正相关关系。结论低氧、氧化应激促使神经元NO产生增多,NO有增加氧自由基对神经细胞的损伤作用。SOD具有清除氧自由基和减轻NO对神经元的损伤作用。     

唾液酯酶多态性在个体识别中的应用研究

目的 探讨唾液酯酶（ Set）多态性在法医学亲权鉴定和个体识别方面的应用价值。方法 应用聚丙烯酰胺凝胶盘状电泳及固蓝 RR染色方法,调查了 114名中国人 Set的表型分布及基因频率,用χ 2检验进行统计学分析。结果 中国人酯酶表型频率 Set F 22.81％, Set FS 50.88％, Set S 26.31％ ;基因频率为 SetF 0.482 5, SetS 0.517 5;非父排除机率为 0.187 5,个体识别率为 0.619 9。结论 Set有较高的父权排除率和个体识别率,可作为法医学亲权鉴定和个体识别的重要标记系统之一。     

线粒体 DNA突变与心肌病关系的研究进展

人类某些疾病与线粒体DNA(mtDNA)基因组缺陷有关.本文就mtDNA突变与缺血性心肌病和肥厚型心肌病关系的研究加以回顾.目前的研究大多认为心肌缺血缺氧致氧化磷酸化紊乱,产生氧自由基损伤mtDNA,以及缺氧致氧化磷酸化过度诱导而损伤mtDNA,慢性损伤积累终致mtDNA片断缺失或点突变,主要表现出mtDNA5.0kb、7.4kb缺失及细胞色素b(cytb)基因上C15452A点突变;tRNA基因保守序列突变,致肌肉收缩蛋白合成缺陷,缺陷的收缩蛋白持续而无效的收缩可能会增加心肌对ATP的代谢需求,因此导致心肌肥厚.